Ticker Watch

Taylor, Marisa
April 2007
Red Herring;4/30/2007, Vol. 4 Issue 16, p33
Trade Publication
The article presents information on the experimental drug AGI-1067, being tested by Alpharetta, Georgia-based biotechnology company Atherogenics, to treat heart disease. The drug aimed to curb inflammatory response, and pharmaceutical giant AstraZeneca went into partnership to push it along. Scientists and analysts were intrigued, and they waited in anticipation for results from clinical trials. AGI-1067 could be the future of cardiovascular medicine, after all. But then late-phase trials of AGI-1067 failed to reduce incidence of heart attack, cardiovascular death, stroke, unstable angina, and other ailments. And analysts tore into the results, putting Atherogenic's stock in a freefall.


Related Articles

  • AstraZeneca: further setbacks ARISE.  // PharmaWatch: Monthly Review;May2007, Vol. 6 Issue 5, p11 

    The article focuses on the failure of the cardiovascular agent AGI-1067 in the phase III ARISE clinical trial. The drug is manufactured by AstraZeneca PLC. The trial was conducted by AstraZeneca and AtheroGenics Inc. to evaluate the safety of the drug in the treatment of patients with acute...

  • Treatment of Heart Failure with Spironolactone – Trial and Tribulations. McMurray, John J.V.; O'Meara, Eileen // New England Journal of Medicine;8/5/2004, Vol. 351 Issue 6, p526 

    The article presents an editorial regarding a clinical trial by Juurlink and colleagues in this issue of the journal, titled the Randomized Aldactone Evaluation Study (RALES), which looked at the treatment of heart failure with spironolactone. The clinical trial showed a low incidence of adverse...

  • Impulse completes enrollment in FIX-HF-5 trial.  // Medical Technology & Devices Week;6/11/2007, Vol. 5 Issue 24, p5 

    The article reports the completion of the patient enrollment in the Fix Heart Failure 5 (FIX-HF-5) study of Impulse Dynamics for its Optimizer III device. Based on the article, the study is the largest randomized clinical trial of Impulse to date and is aimed to evaluate the safety and efficacy...

  • Stem Cell Therapy Linked to Heart Failure Recovery.  // BioPharm International;Jul2005, Vol. 18 Issue 7, p12 

    Reports that a clinical trial has revealed that advanced heart failure patients treated with stem cell therapy show an average 41 percent improvement in their hearts' pumping efficiency. Data points of 10 patients who had received injections of stem cells into their hearts; Increase in the...

  • Clinical brief.  // New Zealand Doctor;6/2/2004, p21 

    Reports on a research which tested a cardiac resynchronization therapy device for heart failure patients, which was published in the 2004 issue of "New England Journal of Medicine." Classification of clinical trial patients; Implications of the study's findings for heart failure treatment.

  • American Heart Association.  // BioWorld Today;11/17/2009, Vol. 20 Issue 222, p9 

    This article focuses on the interim data obtained by Aastrom Biosciences Inc. from the Phase II trial of its Cardiac Repair Cells (CRC). According to the study, patients treated with CRC showed improvement in their heart failure classification. The study also found that there was improved...

  • Calcium Cycling Proteins and Their Association With Heart Failure. Hadri, L.; Hajjar, R. J. // Clinical Pharmacology & Therapeutics;Oct2011, Vol. 90 Issue 4, p620 

    The article focuses on the association of calcium cycling proteins with heart failure (HF) which reached epidemic proportions in the U.S. It notes the significance of calcium cycling protein dysregulation in the HF pathophysiology. It points out that HF reversal through gene transfer become...

  • Should treatment for heart failure with preserved ejection fraction differ from that for heart failure with reduced ejection fraction? Jong, Philip; McKelvie, Robert; Yusuf, Salim // BMJ: British Medical Journal (Overseas & Retired Doctors Edition;8/28/2010, Vol. 341 Issue 7770, p453 

    In this article, the authors seek to clarify whether treatments that are effective in heart failure with reduced ejection fraction (HF-REF) may also be effective in heart failure with preserved ejection fraction (HP-PEF). Data on studies that tested treatments for HF-REF and HP-PEF were sorted...

  • Treatment of heart failure. Mead, Mike // Practice Nurse;5/14/2004, Vol. 27 Issue 9, p44 

    Highlights clinical trials that provided the evidence base for diagnosis and therapy for heart failure. Percentage of the population affected by heart failure; Data on the Studies of Left Ventricular Dysfunction trial using angiotensin converting enzyme inhibitors; Benefits using angiotensin...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics